COVID-19
Conditions
Brief summary
Observe the efficacy and safety of G1(Sildenafil citrate tablets) in patients with COVID-19 under clinical actual diagnosis and treatment conditions
Interventions
DRUGSildenafil citrate tablets
0.1g/day for 14 days
Sponsors
Tongji Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Patients diagnosed as COVID-19: 1. mild patient: fever,respiratory and other symptoms, the manifestation of pneumonia can be seen on imaging. 2. severe patients: meet the definition of severe pneumonia(comply with any of the followings): Shortness of breath,RR≥30 bpm;In a resting state:SPO2≤93%;PaO2/FiO2≤300mmHg. 2. Age≥18 years old,unlimited gender. 3. Patients who cannot stop the following drugs during the trial:erythromycin or strong inhibitors of CYP3A4 (such as saquinavir,ketoconazole,itraconazole),nonspecific inhibitors of CYP (such as cimetidine),HIV protease inhibitors (such as ritonavir). 4. Willing to participate in this study,signed Informed Consent and willing to participate in regular follow-up during the study.
Exclusion criteria
1. Suffer from severe cognitive impairment or mental illness. 2. Pregnant and lactating women. 3. Patients taking nitric oxide drugs and nitrates in any dosage form. 4. Patients with malignant tumors;AMI, stroke or life-threatening arrhythmias within 6 months;hereditary pigmented retinitis;heart failure or unstable angina pectoris of coronary heart disease;patients with severe hypotension and hypertension. 5. Patients who are allergic to the study drug or the researcher believes it is not appropriate. 6. Participate in other clinical studies at the same time.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Rate of disease remission | 14 days | 1. fever,cough and other symptoms relieved with improved lung CT; 2. SPO2\>93% or PaO2/FiO2 \>300mmHg without oxygen inhalation. |
| Rate of entering the critical stage | 14 days | Comply with any of the followings: 1. Respiratory failure occurs and requires mechanical ventilation; 2. Shock; 3. Patients combined with other organ failure need ICU monitoring and treatment. |
| Time of entering the critical stage | 14 days | Comply with any of the followings: 1. Respiratory failure occurs and requires mechanical ventilation; 2. Shock; 3. Patients combined with other organ failure need ICU monitoring and treatment. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Rate of C-reactive protein (CRP) recovery | 14 days | — |
| Rate of Biochemical criterion (CK, ALT, Mb) recovery | 14 days | — |
| Rate of no fever | 14 days | — |
| Time for hospitalization | 14 days | From the date of enrollment to the time when the subject is released from the hospital or transferred to the corresponding department for treatment of other diseases according to the condition. |
| Rate of adverse event | 14 days | All adverse events will be coded and described using the International Medical Terms Dictionary (MedDRA). |
| Rate of undetectable viral RNA (continuous twice) | 14 days | — |
| Rate of respiratory symptom remission | 14 days | — |
| Rate of lung imaging recovery | 14 days | — |
Countries
China
Contacts
Primary ContactQing Ning, Professor
Backup ContactMeifang Han, Professor
Outcome results
None listed